Filing Flows › 8-K events › Aquestive Therapeutics

Aquestive Therapeutics: results of operations

Form 8-K filed Nov 3, 2026 · items 2.02, 7.01

FDA decisionsAquestive Therapeutics Reports Third Quarter 2026 Financial Results

What the filing says

Aquestive Therapeutics Reports Third Quarter 2026 Financial Results • Anaphylm resubmission accepted with PDUFA goal date of March 16, 2027

Read the filing on SEC EDGAR →

What usually followsAcross 69,115 8-Ks reporting Item 2.02 (results of operations) in our universe, the stock's median move the next session was +0.2% (typical size ±3.6%, up 51% of the time); over the following 21 sessions, +1.2%. Every item ranked →

Aquestive Therapeutics at a glance

Latest quarterQ3 2026

Revenue$7.6M

Revenue Y/Y-41%

Operating margin-191.5%

IndustryPharmaceutical Preparations

Aquestive Therapeutics, Q3 2026: revenue $7.6M (-41% year over year), operating margin -191.5%. The chart follows the revenue to costs, profit and cash.

Aquestive Therapeutics: every quarter, Q/Q and Y/Y, holders and guidance →

Other recent fda decisions

Biovie Nov 6, 2026
Acrivon Therapeutics Nov 6, 2026
Entera Bio Nov 6, 2026
Precision Biosciences Nov 5, 2026
Sintx Technologies Nov 5, 2026
Microbot Medical Nov 5, 2026
Bioxytran Nov 5, 2026
Palvella Therapeutics Nov 5, 2026
ANI Pharmaceuticals Nov 5, 2026
Teleflex Nov 5, 2026

Read automatically from SEC EDGAR (13F, Form 4, Form 144, Schedule 13D/G, 8-K, XBRL), House and Senate disclosures, FINRA and exchange data; errors are possible. Not investment advice.